Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)

NCT00545012 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00545012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00545012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2000
Completion date
May 31, 2003
Enrollment
4 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

absence seizures